Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
about
Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonismThe Link between Depression and Chronic Pain: Neural Mechanisms in the Brain.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.HCN Channel Targets for Novel Antidepressant Treatment.EXPRESS: Histone hyperacetylation modulates spinal type II metabotropic glutamate receptor alleviating stress-induced visceral hypersensitivity in female ratsStudy of the Serum Copper Levels in Patients with Major Depressive Disorder.Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model.The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal CortexBiological hypotheses and biomarkers of bipolar disorder.Increased EphA4-ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype.Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects.Acupuncture for behavioral changes of experimental depressive disorder: a systematic review and meta-analysis.P2X7 Receptors Drive Spine Synapse Plasticity in the Learned Helplessness Model of Depression.Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMTDifferential expression of postsynaptic NMDA and AMPA receptor subunits in the hippocampus and prefrontal cortex of the flinders sensitive line rat model of depression.Lisdexamfetamine Effects on Executive Activation and Neurochemistry in Menopausal Women with Executive Function Difficulties.Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function.The effect of ethanolic extract of Thymus kotschyanus on cancer cell growth in vitro and depression-like behavior in the mouse.Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine.Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression.Serotonin in psychiatry: in vitro disease modeling using patient-derived neurons.Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor.Chemicogenetic Restoration of the Prefrontal Cortex to Amygdala Pathway Ameliorates Stress-Induced Deficits.Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.Stress-Induced Functional Alterations in Amygdala: Implications for Neuropsychiatric Diseases.Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.Leptin in depression: a potential therapeutic targetKetamine Reverses Lateral Habenula Neuronal Dysfunction and Behavioral Immobility in the Forced Swim Test Following Maternal Deprivation in Late Adolescent Rats
P2860
Q33842686-BB7201E2-785F-40F4-AA72-AA07EEF0AF8CQ33863747-204C4753-B3E6-4EFF-8C69-F3FE026F9227Q34551188-2A311B5A-F29C-4D8B-9555-39BCB1E8A7A4Q34557298-6C0ACB26-D58A-47CE-96F3-8165EEB13A1BQ37115172-804AB35F-A9DC-4C3F-95A5-90457BA46700Q37385662-FEDA3AEC-C0D8-4749-BCD1-9905CEE2F4ACQ37547285-93C8DAE1-B10A-4C8D-8B05-B0FC08EF7A6DQ37633118-519F1CAA-1BFA-401A-80EB-1FE56F1B03DFQ38995726-24D72E64-5331-425C-A58C-3C86DAF3953BQ40097393-4AB26216-768F-430D-AE90-E63D6CC2DA6CQ40229544-7A2F6554-1494-4AC4-97A7-4FFC1C42F012Q41550695-0BD54C24-85ED-401A-88EC-D2183770F3C0Q42010874-C37EADA6-1CED-4295-AA43-578C65F75348Q42253326-79E8D882-DFD4-4D3A-B694-D434970B2925Q42373861-614E597A-5328-4BCA-B217-398894068E50Q46336190-DCBB712D-6ADC-415F-B467-41E5DD26DA7DQ47149797-CE45AAB3-B3D3-45B1-B51D-3240160DFD49Q47263378-D9431246-633B-4AE9-BF9F-DA87B9C067D8Q47658740-2B6BE3D0-2D0D-4972-B02F-B7D1BC09C3E8Q47662037-9492E2C7-1FE5-4A86-99BE-8BD1AE35C6C7Q47783464-D4E89191-3998-41B1-8824-7403E08ABB9BQ47796188-2D4D4748-E221-49D8-9110-866847DAFEB4Q47963007-EFB4BE0C-DFCB-4D56-A74C-298A7AF71408Q49914169-7C765139-84F7-4960-BD86-832DA0F2B019Q50583805-EF276452-B71D-400D-9126-FC61E9471B75Q53838133-AF8E94DA-4B3D-49DF-A496-1D3F6CB5A545Q55312337-1AC643FA-EABE-4E32-9CE8-A1BC87637075Q55438088-29683447-737F-4821-A172-0297F107C251Q58113193-DDD53F20-00C8-4CA2-90EE-F014CE1968AEQ58693900-F3E28369-1C1C-4300-BBBB-AC6FEFDF7269
P2860
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@ast
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@en
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@nl
type
label
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@ast
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@en
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@nl
prefLabel
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@ast
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@en
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@nl
P2093
P2860
P1433
P1476
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
@en
P2093
Danielle M Gerhard
Eric S Wohleb
Ronald S Duman
P2860
P304
P356
10.1016/J.DRUDIS.2016.01.016
P577
2016-02-05T00:00:00Z